IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates

Aug. 29, 2022 6:15 PM ETIGM Biosciences, Inc. (IGMS)SNYBy: Jonathan Block, SA News Editor1 Comment

Wall Street sign

stu99

  • BofA Securities has initiated IGM Biosciences (NASDAQ:IGMS) with a buy on advantages the company's IgM antibodies in development have over existing antibody therapies.
  • The firm has a $34 price target on shares (~79% upside based on Monday's close).

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.